Accumulation of the sigma-1 receptor is common to neuronal nuclear inclusions in various neurodegenerative diseases

Neuropathology

Volumn 34, Issue 2, 2014, Pages 148-158

  Miki, Yasuo ^a   Mori, Fumiaki ^a   Kon, Tomoya ^a   Tanji, Kunikazu ^a   Toyoshima, Yasuko ^b   Yoshida, Mari ^c   Sasaki, Hidenao ^d   Kakita, Akiyoshi ^b   Takahashi, Hitoshi ^b   Wakabayashi, Koichi ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

^c AICHI MEDICAL UNIVERSITY   (Japan)

^d HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chaperone; Endoplasmic reticulum; Neuronal nuclear inclusion; Polyglutamine disease; Sigma 1 receptor

Indexed keywords

EXPORTIN 1; LEPTOMYCIN B; PROTEIN P62; SIGMA 1 OPIATE RECEPTOR; THAPSIGARGIN; DNA BINDING PROTEIN; PROTEIN TDP-43; SIGMA OPIATE RECEPTOR; SIGMA-1 RECEPTOR;

ADULT; AGED; ALPHA SYNUCLEINOPATHY; ARTICLE; ASTROCYTE; BRAIN; CELL CULTURE; CELL INCLUSION; CELL NUCLEUS INCLUSION BODY; CONTROLLED STUDY; CYTOPLASM; CYTOSOLIC FRACTION; DEGENERATIVE DISEASE; ENDOPLASMIC RETICULUM STRESS; GLIA CELL; HIPPOCAMPAL SCLEROSIS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTRANUCLEAR INCLUSION BODY DISEASE; NERVE CELL; NEURONAL NUCLEAR INCLUSION; NISSL SUBSTANCE; OLIGODENDROGLIA; PATHOGENESIS; POLYGLUTAMINE DISEASE; PRIORITY JOURNAL; SPINAL CORD; TAUOPATHY; TDP 43 PROTEINOPATHY; VERY ELDERLY; WESTERN BLOTTING; AUTOPSY; BIOSYNTHESIS; GENETICS; HELA CELL LINE; METABOLISM; PATHOLOGY;

AUTOPSY; CELLS, CULTURED; DNA-BINDING PROTEINS; HELA CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; INTRANUCLEAR INCLUSION BODIES; NEURODEGENERATIVE DISEASES; RECEPTORS, SIGMA; TDP-43 PROTEINOPATHIES;

EID: 84898057760     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/neup.12080     Document Type: Article

References (63)

1. Hayashi T, Tsai SY, Mori T, Fujimoto M, Su TP. Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders. Expert Opin Ther Targets 2011; 5: 557-577.
2. Kekuda R, Prasad PD, Fei YJ, Leibach FH, Ganapathy V. Cloning and functional expression of the human type 1 sigma receptor (hSigmaR1). Biochem Biophys Res Commun 1996; 229: 553-558.
3. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE. The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 1976; 197: 517-532.
4. Quirion R, Bowen WD, Itzhak Y etal. A proposal for the classification of sigma binding sites. Trends Pharmacol Sci 1992; 13: 85-86.
5. Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca (2+) signaling and cell survival. Cell 2007; 131: 596-610.
6. Lupardus PJ, Wilke RA, Aydar E etal. Membrane-delimited coupling between sigma receptors and K+ channels in rat neurohypophysial terminals requires neither G-protein nor ATP. J Physiol 2000; 526: 527-539.
7. Renaudo A, L'hoste S, Guizouarn H, Borgèse F, Soriani O. Cancer cell cycle modulated by a functional coupling between sigma-1 receptors and Cl- channels. J Biol Chem 2007; 282: 2259-2267.
8. Tsai SY, Hayashi T, Harvey BK etal. Sigma-1 receptors regulate hippocampal dendritic spine formation via a free radical-sensitive mechanism involving Rac1xGTP pathway. Proc Natl Acad Sci U S A 2009; 106: 22468-22473.
9. Zhang H, Cuevas J. Sigma receptor activation blocks potassium channels and depresses neuroexcitability in rat intracardiac neurons. J Pharmacol Exp Ther 2005; 313: 1387-1396.
10. Schröder MM, Kaufman RJ. The mammalian unfolded protein response. Annu Rev Biochem 2005; 74: 739-789.
11. Roussel BD, Kruppa AJ, Miranda E etal. Endoplasmic reticulum dysfunction in neurological disease. Lancet Neurol 2013; 12: 105-118.
12. Colla E, Jensen PH, Pletnikova O etal. Accumulation of toxic α-synuclein oligomer within endoplasmic reticulum occurs in α-synucleinopathy in vivo. J Neurosci 2012; 32: 3301-3305.
13. Luty AA, Kwok JB, Dobson-Stone C etal. Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease. Ann Neurol 2010; 68: 639-649.
14. Al-Saif A, Al-Mohanna F, Bohlega S. A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis. Ann Neurol 2011; 70: 913-919.
15. Kudo N, Matsumori N, Taoka H etal. Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci U S A 1999; 96: 9112-9117.
16. Mackenzie IR, Neumann M, Baborie A etal. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 2011; 122: 111-113.
17. Miki Y, Mori F, Hori E, Kaimori M, Wakabayashi K. Hippocampal sclerosis with four-repeat tau-positive round inclusions in the dentate gyrus: a new type of four-repeat tauopathy. Acta Neuropathol 2009; 117: 713-718.
18. Toyoshima Y, Tanaka H, Shimohata M etal. Spinocerebellar ataxia type 2 (SCA2) is associated with TDP-43 pathology. Acta Neuropathol 2011; 122: 375-378.
19. Zhang HX, Tanji K, Mori F etal. Epitope mapping of 2E2-D3, a monoclonal antibody directed against human TDP-43. Neurosci Lett 2008; 434: 170-174.
20. Mori F, Toyoshima Y, Tanji K etal. FUS co-localizes with polyglutamine, but not with TDP-43 in neuronal intranuclear inclusions in spinocerebellar ataxia type 2. Neuropathol Appl Neurobiol 2013. doi: 10.1111/nan.12075
21. Nagaoka U, Kim K, Jana NR etal. Increased expression of p62 in expanded polyglutamine-expanding cells and its association with polyglutamine inclusions. J Neurochem 2004; 91: 57-68.
22. Mori F, Tanji K, Odagiri S etal. Autophagy-related proteins (p62, NBR1 and LC3) in intranuclear inclusions in neurodegenerative diseases. Neurosci Lett 2012; 522: 134-138.
23. Pankiv S, Lamark T, Bruun JA etal. Nucleocytoplasmic shuttling of p62/SQSTM1 and its role in recruitment of nuclear polyubiquitinated proteins to promyelocytic leukemia bodies. J Biol Chem 2010; 285: 5941-5953.
24. Kawaguchi Y, Okamoto T, Taniwaki M etal. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet 1994; 8: 221-228.
25. Koide R, Ikeuchi T, Onodera O etal. Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA). Nat Genet 1994; 6: 9-13.
26. Martindale D, Hackam A, Wieczorek A etal. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat Genet 1998; 18: 150-154.
27. Nagafuchi S, Yanagisawa H, Sato K etal. Dentatorubral and pallidoluysian atrophy expansion of an unstable CAG trinucleotide on chromosome 12p. Nat Genet 1994; 6: 14-18.
28. Orr HT, Chung MY, Banfi S etal. Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat Genet 1993; 4: 221-226.
29. Pulst SM, Nechiporuk A, Nechiporuk T etal. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat Genet 1996; 14: 269-276.
30. Arrasate M, Mitra S, Schweitzer ES etal. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004; 431: 805-810.
31. Morfini G, Pigino G, Brady ST. Polyglutamine expansion diseases: failing to deliver. Trends Mol Med 2005; 11: 64-70.
32. Nagai Y, Inui T, Popiel HA etal. A toxic monomeric conformer of the polyglutamine protein. Nat Struct Mol Biol 2007; 14: 332-340.
33. Ayala V, Granado-Serrano AB, Cacabelos D etal. Cell stress induces TDP-43 pathological changes associated with ERK1/2 dysfunction: implications in ALS. Acta Neuropathol 2011; 122: 259-270.
34. Kimber TE, Blumbergs PC, Rice JP etal. Familial neuronal intranuclear inclusion disease with ubiquitin positive inclusions. J Neurol Sci 1998; 160: 33-40.
35. Mori F, Miki Y, Tanji K etal. Incipient intranuclear inclusion body disease in a 78-year-old woman. Neuropathology 2011; 31: 188-193.
36. Pountney DL, Huang Y, Burns RJ etal. SUMO-1 marks the nuclear inclusions in familial neuronal intranuclear inclusion disease. Exp Neurol 2003; 184: 436-446.
37. Takahashi-Fujigasaki J, Arai K, Funata N, Fujigasaki H. SUMOylation substrates in neuronal intranuclear inclusion disease. Neuropathol Appl Neurobiol 2006; 32: 92-100.
38. Mcfadden K, Hamilton RL, Insalaco SJ etal. Neuronal intranuclear inclusion disease without polyglutamine inclusions in a child. J Neuropathol Exp Neurol 2005; 64: 545-552.
39. Suzuki K, Sato T, Yamada M etal. DRPLA: recent advances in research using transgenic mouse models. Methods Mol Biol 2013; 1010: 277-292.
40. Bancher C, Lassmann H, Budka H etal. An antigenic profile of Lewy bodies: immunocytochemical indication for protein phosphorylation and ubiquitination. J Neuropathol Exp Neurol 1989; 48: 81-93.
41. Dickson DW, Wertkin A, Kress Y, Ksiezak-Reding H, Yen SH. Ubiquitin immunoreactive structures in normal human brains. Distribution and developmental aspects. Lab Invest 1990; 63: 87-99.
42. Kuusisto E, Kauppinen T, Alafuzoff I. Use of p62/SQSTM1 antibodies for neuropathological diagnosis. Neuropathol Appl Neurobiol 2008; 34: 160-180.
43. Fujigasaki H, Uchihara T, Takahashi J etal. Preferential recruitment of ataxin-3 independent of expanded polyglutamine: an immunohistochemical study on Marinesco bodies. J Neurol Neurosurg Psychiatry 2001; 71: 518-520.
44. Kettner M, Willwohl D, Hubbard GB etal. Intranuclear aggregation of nonexpanded ataxin-3 in Marinesco bodies of the nonhuman primate substantia nigra. Exp Neurol 2002; 176: 117-121.
45. Kumada S, Uchihara T, Hayashi M etal. Promyelocytic leukemia protein is redistributed during the formation of intranuclear inclusions independent of polyglutamine expansion: an immunohistochemical study on Marinesco bodies. J Neuropathol Exp Neurol 2002; 61: 984-991.
46. Mizuno Y, Hori S, Kakizuka A, Okamoto K. Vacuole-creating protein in neurodegenerative diseases in humans. Neurosci Lett 2003; 343: 77-80.
47. Fujigasaki H, Uchihara T, Kayano S etal. Ataxin-3 is translocated into the nucleus for the formation of intranuclear inclusions in normal and Machado-Joseph disease brains. Exp Neurol 2000; 165: 248-256.
48. Hirabayashi M, Inoue K, Tanaka K etal. VCP/p97 is abnormal protein aggregates, cytoplasmic vacuoles, and cell death, phonotypes relevant to neurodegeneration. Cell Death Differ 2001; 8: 977-984.
49. Takahashi J, Fujigasaki H, Iwabuchi K etal. PML nuclear bodies and neuronal intranuclear inclusion in polyglutamine diseases. Neurobiol Dis 2003; 13: 230-237.
50. Yamada M, Satoh T, Shimohata T etal. Interaction between neuronal intranuclear inclusions and promyelocytic leukemia protein nuclear and coiled bodies in CAG repeat diseases. Am J Pathol 2001; 159: 1785-1795.
51. Nucifora FC Jr, Sasaki M, Peters MF etal. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 2001; 291: 2423-2428.
52. Shimohata T, Nakajima T, Yamada M etal. Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nat Genet 2000; 26: 29-36.
53. Atwal RS, Xia J, Pinchev D etal. Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. Hum Mol Genet 2007; 16: 2600-2615.
54. Atwal RS, Truant R. A stress sensitive ER membrane-association domain in Huntingtin protein defines a potential role for Huntingtin in the regulation of autophagy. Autophagy 2008; 4: 91-93.
55. Xia J, Lee DH, Taylor J, Vandelft M, Truant R. Huntingtin contains a highly conserved nuclear export signal. Hum Mol Genet 2003; 12: 1393-1403.
56. Irwin S, Vandelft M, Pinchev D etal. RNA association and nucleocytoplasmic shuttling by ataxin-1. J Cell Sci 2005; 118: 233-242.
57. Scaglione KM, Zavodszky E, Todi SV etal. Ube2w and ataxin-3 coordinately regulate the ubiquitin ligase CHIP. Mol Cell 2011; 43: 599-612.
58. Paulson HL, Perez MK, Trottier Y etal. Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 1997; 19: 333-344.
59. Reina CP, Zhong X, Pittman RN. Proteotoxic stress increases nuclear localization of ataxin-3. Hum Mol Genet 2010; 19: 235-249.
60. Arai T, Nonaka T, Hasegawa M etal. Neuronal and glial inclusions in frontotemporal dementia with or without motor neuron disease are immunopositive for p62. Neurosci Lett 2003; 342: 41-44.
61. Kuusisto E, Salminen A, Alafuzoff I. Ubiquitin-binding protein p62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies. Neuroreport 2001; 12: 2085-2090.
62. Bjørkøy G, Lamark T, Brech A etal. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol 2005; 171: 603-614.
63. Seibenhener ML, Babu JR, Geetha T etal. Sequestosome 1/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation. Mol Cell Biol 2004; 24: 8055-8068.